Benefits with pain and nociceptive assessment
Pain, the 5th vital sign, affects the quality of life for billions of people worldwide.
Pain, the 5th vital sign, affects the quality of life for billions of people worldwide.
Pain was defined as the 5th vital sign in 2002 by the US government, and pain is mandatory to assess in US, Russia, and most of the countries in Europe. Since then the satisfaction from patients has increased. However the deaths caused by respiratory depression due to opioids have also increased, as well as addiction to opioids (1.2.).
Assessing and treating pain is therefore in high focus in medicine and is essential for every clinician. If pain is not managed the patients can have delayed recovery, increased morbidity and mortality. In the US alone, the annual healthcare costs exceeds $600 billion.
The golden standard to assess pain is reported pain which is influenced by factors like anxiety, depression, previously painful events, existing pain and demographics due to the fact that pain experiences are being processed in the brain (supra spinal level) before reported. An objective assessment of pain and nociceptive stimuli enables clinicians to tailor the need of analgesia when needed. The PainMonitor device based on skin conductance changes, which is based on a nociceptive spinal reflex (3), is not influenced by e.g. anxiety levels in the peri-operative setting or changes in blood circulation. The PainMonitor device is therefore the most exact way of tailoring the level of analgesia to avoid opioid adverse effects in all patient groups during anaesthesia, in intensive care patients, postoperatively as well as in preterm infants.